SCHEMBL22096031

SCHEMBL22096031

O=C(O)c1nonc1NCn1nnnc1CCCCc1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 4/20 0.78
DAGLA Q9Y4D2 4/20 0.42
ASPH Q12797 2/20 0.37
KDM8 Q8N371 2/20 0.37
ALDH1A1 P00352 3/20 0.37
HSD11B1 P28845 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ASAH1 Q13510 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20047849 0.98 STAT5B (0.78) STAT5BDAGLAASPHKDM8ALDH1A1
SCHEMBL22096030 0.94 STAT5B (0.82) STAT5BDAGLAALDH1A1HSD11B1CYP1A2
SCHEMBL20048221 0.88 STAT5B (1.00) STAT5BDAGLAALDH1A1HSD11B1CYP1A2
SCHEMBL22096037 0.86 STAT5B (0.73) STAT5BDAGLAALDH1A1HSD11B1CYP1A2
SCHEMBL22096032 0.85 STAT5B (0.78) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22096039 0.84 STAT5B (0.77) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22096036 0.83 STAT5B (0.69) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22096011 0.82 STAT5B (0.88) STAT5BALDH1A1TRPV1
SCHEMBL22096014 0.81 STAT5B (0.66) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22096035 0.81 STAT5B (0.72) STAT5BALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885DAGLA 3328/4885ASPH 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.